Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $135.4 thousand for the year ending 2022.
- ENDONOVO THERAPEUTICS, INC. showed an increase of +85.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
- This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
- XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2018 to 2022), ENDONOVO THERAPEUTICS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 62.6%.
- Historical annual values: Fiscal year 2022: $135.4 thousand | Fiscal year 2021: $73.1 thousand | Fiscal year 2020: $165.8 thousand | Fiscal year 2019: $310.2 thousand | Fiscal year 2018: $83.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: